← All trials
NCT05861128
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2024
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2025
- First posted
- May 16, 2023
- Last posted
- Jul 11, 2023
- Enrollment
- 258
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Suzhou Zelgen Biopharmaceuticals Co.,LtdLead sponsor
- Jiao Tong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.